| Print
Gilead Sciences (GILD)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis Cdrug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Address
333 Lakeside Drive
Foster
CA
USA
94404
Telephone
+1 650 574-3000
Forecast key dates
| Name | Key Date |
|---|---|
| Gilead Sciences Inc Third Quarter Earnings Conference Call for 2027 | 2027-10-29T16:30:00 |
| Gilead Sciences Inc Third Quarter Earnings Results for 2027 | 2027-10-29T00:00:00 |
| Gilead Sciences Inc Second Quarter Earnings Conference Call for 2027 | 2027-08-04T16:30:00 |
| Gilead Sciences Inc Second Quarter Earnings Results for 2027 | 2027-08-04T00:00:00 |
| Gilead Sciences Inc First Quarter Earnings Conference Call for 2027 | 2027-05-07T16:30:00 |
| Gilead Sciences Inc First Quarter Earnings Results for 2027 | 2027-05-07T00:00:00 |
| Gilead Sciences Inc Annual General Meeting for 2027 | 2027-04-30T10:00:00 |
| Gilead Sciences Inc Annual Report for 2026 | 2027-02-24T00:00:00 |
| Gilead Sciences Inc Fourth Quarter Earnings Conference Call for 2026 | 2027-02-10T16:30:00 |
| Gilead Sciences Inc Fourth Quarter Earnings Results for 2026 | 2027-02-10T00:00:00 |
| Gilead Sciences Inc Third Quarter Earnings Conference Call for 2026 | 2026-10-29T16:30:00 |
| Gilead Sciences Inc Third Quarter Earnings Result for 2026 | 2026-10-29T00:00:00 |